Location: Infectious Bacterial Diseases ResearchTitle: Sustained antigen release, polyanhydride-based vaccine platform for immunixation against bovine brucellosis
|SCHAUT, ROBERT - US Department Of Agriculture (USDA)|
|KANIPE, CARLY - US Department Of Agriculture (USDA)|
|KELLY, SEAN - Iowa State University|
|NARASIMHAN, BALAJI - Iowa State University|
|JONES, DOUGLAS - Iowa State University|
Submitted to: Heliyon
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 8/22/2019
Publication Date: 8/29/2019
Citation: Boggiatto, P.M., Schaut, R.G., Kanipe, C., Kelly, S.M., Narasimhan, B., Jones, D.E., Olsen, S.C. 2019. Sustained antigen release, polyanhydride-based vaccine platform for immunixation against bovine brucellosis. Heliyon. 5(8). https://doi.org/10.1016/j.heliyon.2019.e02370.
Interpretive Summary: Brucella spp. are intracellular bacteria that cause persistent infections in the mammalian host. Vaccination has been the most effective way to reduce disease prevalence. There are no human vaccines and despite the success of animal vaccines, there is continued need need for the development of safer and effective Brucella vaccines. Here we report the use of a single dose, biodegradable polymer-based delivery platform containing whole killed brucella as a novel vaccination strategy. This work will be of interest to scientists, regulatory personnel, and producers as a novel and safe approach to vaccination.
Technical Abstract: Brucellosis is a bacterial zoonosis and a significant source of financial loss and a major public health concern, worldwide. Bovine brucellosis, as caused primarily by Brucella abortus, is an economically important cause of reproductive loss in cattle. Vaccination has been the most effective way to reduce disease prevalence and has contributed to the success of control and eradication programs. Currently, there are no human vaccines available, and despite the success of commercial vaccines for livestock, such as B. abortus strain RB51 (RB51), there is continued interest for development of novel vaccines against brucellosis. In the current study, we report the fabrication and immune responses of cattle to an implantable single dose 20:80 CPTEG:CPH polymer-based, methanol-killed RB51 antigen-containing delivery platform (PolyVax). As compared to animals vaccinated with RB51, we did not observe measurable RB51-specific IgG or IFN-gamma delta responses in the peripheral blood, following initial vaccination PolyVax. However, following a subsequent booster vaccination with RB51, we observed an anamnestic response in both vaccination treatments (PolyVax and live RB51). CD4+ IFN-gamma delta-mediated responses and circulating memory T cell subpopulations were comparable between the two vaccination treatments, while IgG titers were significantly increased in animals vaccinated with PolyVax as compared to live RB51-vaccinated animals. The data presented here demonstrate that killed antigen can be utilized to generate IFN-gamma delta-mediated, CD4+ T cell and humoral responses against Brucella in a natural host. Our data suggest that perhaps the manner in which killed antigen is presented may affect the course of the immune response. To our knowledge, this novel approach to vaccination against intracellular bacteria, such as Brucella, has not been reported before.